Cambridge Cognition PLC has announced a strategic partnership with Luca Healthcare Ltd to expand its operations in China.
Cambridge Cognition is a Cambridge-based brain health assessment software provider, while Luca Healthcare provides clinically validated software-based screening, tracking and treatment to patients in China.
The exclusive license agreement allows Cambridge Cognition to commercialize the company’s suite of leading cognitive assessment tools in China for both the pharmaceutical and healthcare markets.
The strategic partnership provides an "efficient and low-risk geographic expansion", the firm says.
According to the news report, Cambridge Cognition said that China is the second most active clinical trial market in the world after the US. China has hosted nearly 10,000 industry-sponsored trials in the last five years with 14% being in Central Nervous System conditions.
Join our Masterclass on ‘The New Reimbursement Pathway in France’ on 30th November. Click here to Request to Join.
Click here to read the original news article.